TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06641908: Anti-GD2 ADC M3554 in Advanced Solid Tumors

Sponsor: EMD Serono Research & Development Institute, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT06641908 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06641908 Rescue Dossier →